Evidence reviews - December 2022
The following documents contain the evidence that was used to develop the 2022 recommendations:
- Ultrasound accuracy and threshold of nodule size and classification
- Indications for blood tests
- Radioisotope scan
- Diagnostic accuracy of fine needle aspiration cytology
- Efficacy of repeat fine needle aspiration cytology, active surveillance or discharge
- Molecular testing
- Imaging for further staging
- Initial treatments for differentiated thyroid cancer
- Thyrotropin alfa
- Radioactive iodine versus no radioactive iodine
- Activity of radioactive iodine after thyroidectomy
- External beam radiotherapy versus no external beam radiotherapy
- Thyroid stimulating hormone (TSH) suppression versus no TSH suppression
- Duration of thyroid stimulating hormone suppression
- Measurement of thyroglobulin
- Stimulated or highly sensitive thyroglobulin assays
- Length and frequency of follow up
- Information, education and support needed by people with suspected and confirmed thyroid cancer, and their families and carers
Other supporting evidence
This page was last updated: